MA43571A - Protéines contenant un domaine riche en cystéine 2 dkk2 et leurs utilisations - Google Patents

Protéines contenant un domaine riche en cystéine 2 dkk2 et leurs utilisations

Info

Publication number
MA43571A
MA43571A MA043571A MA43571A MA43571A MA 43571 A MA43571 A MA 43571A MA 043571 A MA043571 A MA 043571A MA 43571 A MA43571 A MA 43571A MA 43571 A MA43571 A MA 43571A
Authority
MA
Morocco
Prior art keywords
dkk2
cysteine
proteins containing
field rich
rich
Prior art date
Application number
MA043571A
Other languages
English (en)
Inventor
Joseph W Arndt
Andreas Lehmann
Brenda K Minesinger
Joshua Mugford
Nels E Pederson
R Blake Pepinsky
Richelle Sopko
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA43571A publication Critical patent/MA43571A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA043571A 2015-12-23 2016-12-16 Protéines contenant un domaine riche en cystéine 2 dkk2 et leurs utilisations MA43571A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562387116P 2015-12-23 2015-12-23

Publications (1)

Publication Number Publication Date
MA43571A true MA43571A (fr) 2018-11-14

Family

ID=57794355

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043571A MA43571A (fr) 2015-12-23 2016-12-16 Protéines contenant un domaine riche en cystéine 2 dkk2 et leurs utilisations

Country Status (4)

Country Link
US (1) US20200270335A1 (fr)
EP (1) EP3394265A1 (fr)
MA (1) MA43571A (fr)
WO (1) WO2017112549A1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
DK2567709T3 (en) * 2007-11-02 2018-03-12 Novartis Ag Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6)
WO2010075194A1 (fr) 2008-12-22 2010-07-01 St. Jude Children's Research Hospital Expression procaryote de dkk soluble active
US8748380B2 (en) 2009-10-30 2014-06-10 Novozymes Biopharma Dk A/S Albumin variants
US8697650B2 (en) 2010-02-16 2014-04-15 Medimmune, Llc HSA-related compositions and methods of use
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
EP2705051A1 (fr) 2011-05-05 2014-03-12 Novozymes Biopharma DK A/S Variants de l'albumine
WO2016126054A1 (fr) * 2015-02-04 2016-08-11 (주)메드팩토 Composition pour prévenir ou traiter un trouble de l'érection comprenant une protéine dkk2 modifiée ou un gène pour celle-ci, et son procédé d'utilisation

Also Published As

Publication number Publication date
US20200270335A1 (en) 2020-08-27
WO2017112549A1 (fr) 2017-06-29
EP3394265A1 (fr) 2018-10-31

Similar Documents

Publication Publication Date Title
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA51287A (fr) Analogues d'incrétine et leurs utilisations
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
DK3581190T3 (da) Manipulerede naturlige dræberceller og anvendelser deraf
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
MA50397A (fr) Anticorps anti-tau et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
FR3052453B1 (fr) Peptide, composition le comprenant et utilisations notamment cosmetiques
MA43567A (fr) Anticorps pacap et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
MA44665A (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
MA43738A (fr) Anticorps anti-tnfalpha et leurs fragments fonctionnels
MA47459A (fr) Anticorps anti-tryptase, compositions les contenant et leurs utilisations
MA46036A (fr) Anticorps anti-vegf-a et anti-ang2 et leurs utilisations
MA46945A (fr) Exopolysaccharides et leurs utilisations